Immutep Limited (IMMP)Healthcare | Biotechnology | Sydney, Australia | NasdaqGM
3.21 USD
-0.15
(-4.464%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:14 a.m. EDT
The investment case for Immutep is currently broken by a catastrophic failure in clinical development. The stock has collapsed 80% following the halt of its lung cancer trial, a disaster compounded by a class-action lawsuit alleging securities fraud. While the company recently secured orphan drug designations for other candidates, these glimmers of hope are insufficient to offset the massive capital burn, negative operating cash flow, and the severe damage to credibility caused by the halted trial. The balance sheet, while technically liquid, cannot sustain the prolonged R&D cycle required to recover from such a setback without significant dilution or strategic intervention. The market has correctly priced this as a deep value trap where the probability of a successful turnaround is low enough to justify the current depressed valuation, making it a dangerous hold for investors seeking capital preservation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.182692 |
| MSTL | 0.215502 |
| AutoETS | 0.217215 |
| AutoARIMA | 0.226416 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 9% |
| H-stat | 1774.75 |
| Ljung-Box p | 0.208 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 15.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.702 |
| Revenue per Share | 2.8 |
| Market Cap | 23,653,228 |
| Forward P/E | -0.62 |
| Beta | 2.30 |
| Website | https://www.immutep.com |
As of Oct. 10, 2026, 11:14 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy out-of-the-money puts for October 2026 while call activity is negligible. The implied volatility skew shows significantly higher pricing for downside protection compared to upside potential, indicating a market consensus focused on further decline rather than recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9183575 |
| Address1 | Australia Square |
| Address2 | Level 32, Suite 32.07 264 George Street |
| All Time High | 510.0 |
| All Time Low | 3.06 |
| Ask | 0.5023 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 22,870 |
| Average Daily Volume3 Month | 15,687 |
| Average Volume | 15,687 |
| Average Volume10Days | 22,870 |
| Beta | 2.303 |
| Bid | 0.287 |
| Bid Size | 2 |
| Book Value | 5.861688 |
| City | Sydney |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.21 |
| Current Ratio | 5.694 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.31 |
| Day Low | 3.06 |
| Debt To Equity | 1.702 |
| Display Name | Immutep |
| Dividend Date | 1,482,883,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,788,465,600 |
| Earnings Timestamp Start | 1,788,465,600 |
| Ebitda | -79,403,952 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.556 |
| Enterprise To Revenue | -2.216 |
| Enterprise Value | -44,172,292 |
| Eps Current Year | -4.0 |
| Eps Forward | -5.2 |
| Eps Trailing Twelve Months | -7.3 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 2 8569 1880 |
| Fifty Day Average | 6.3538 |
| Fifty Day Average Change | -3.1437998 |
| Fifty Day Average Change Percent | -0.4947905 |
| Fifty Two Week Change Percent | -91.83575 |
| Fifty Two Week High | 70.6 |
| Fifty Two Week High Change | -67.39 |
| Fifty Two Week High Change Percent | -0.95453256 |
| Fifty Two Week Low | 3.06 |
| Fifty Two Week Low Change | 0.1500001 |
| Fifty Two Week Low Change Percent | 0.04901964 |
| Fifty Two Week Range | 3.06 - 70.6 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,334,842,200,000 |
| Float Shares | 6,865,478 |
| Forward Eps | -5.2 |
| Forward P E | -0.6173077 |
| Free Cashflow | -36,994,360 |
| Full Exchange Name | NasdaqGM |
| Fullday Change | -0.14999986 |
| Fullday Change Percent | -4.4642816 |
| Fullday Price | 3.21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -72,012,816 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.000120000004 |
| Held Percent Institutions | 0.01129 |
| Implied Shares Outstanding | 7,368,607 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,790,553,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. |
| Long Name | Immutep Limited |
| Market | us_market |
| Market Cap | 23,653,228 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_6701589 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -79,304,560 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 42,971,318 |
| Number Of Analyst Opinions | 1 |
| Open | 3.31 |
| Operating Cashflow | -55,463,740 |
| Operating Margins | -2.55737 |
| Phone | 61 2 8315 7003 |
| Previous Close | 3.36 |
| Price Eps Current Year | -0.8025 |
| Price Hint | 4 |
| Price To Book | 0.5476238 |
| Price To Sales Trailing12 Months | 1.186571 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.543 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.15 |
| Regular Market Change Percent | -4.46428 |
| Regular Market Day High | 3.31 |
| Regular Market Day Low | 3.06 |
| Regular Market Day Range | 3.06 - 3.31 |
| Regular Market Open | 3.31 |
| Regular Market Previous Close | 3.36 |
| Regular Market Price | 3.21 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 19,021 |
| Return On Assets | -0.42452 |
| Return On Equity | -0.77307 |
| Revenue Growth | 6.335 |
| Revenue Per Share | 2.8 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 7,368,607 |
| Shares Percent Shares Out | 0.0063 |
| Shares Short | 46,784 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 53,196 |
| Short Name | Immutep Limited |
| Short Percent Of Float | 0.0135 |
| Short Ratio | 1.99 |
| Source Interval | 15 |
| State | NSW |
| Symbol | IMMP |
| Target High Price | 30.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 30.0 |
| Target Median Price | 30.0 |
| Total Cash | 68,873,040 |
| Total Cash Per Share | 9.347 |
| Total Debt | 1,047,526 |
| Total Revenue | 19,934,102 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.34845 |
| Two Hundred Day Average Change | -17.13845 |
| Two Hundred Day Average Change Percent | -0.84224844 |
| Type Disp | Equity |
| Volume | 19,021 |
| Website | https://www.immutep.com |
| Zip | 2,000 |